Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Iain Murray is active.

Publication


Featured researches published by Iain Murray.


European Journal of Endocrinology | 2010

Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT.

Tara Barwick; Iain Murray; Hakim Megadmi; Wm M. Drake; Pn N. Plowman; Sa A. Akker; Sl L. Chew; Ashley B. Grossman; Norbert Avril

OBJECTIVE The aim of the study was to assess the diagnostic performance of co-registered single photon emission computed tomography (SPECT)/computed tomography (CT) compared to Iodine-123 whole body gamma camera (WBGC) imaging and to SPECT alone in patients with differentiated thyroid cancer. METHODS WBGC and SPECT/CT (n=85) imaging of the neck and thorax was performed in 79 consecutive patients. Three experienced observers reviewed: i) WBGC images followed by ii) SPECT alone, and iii) co-registered SPECT/CT. Foci of increased radioiodine uptake were classified on a five-point scale. Biopsy, other imaging modalities, and clinical follow-up served as the reference standard. RESULTS Twenty-two patients had local recurrence or metastatic thyroid cancer (11 were radioiodine negative), 9 had remnant thyroid tissue, and 54 had no evidence of disease. When classifying equivocal, probably, and definitely malignant findings as positive for malignancy, the sensitivity, specificity, positive predictive value, and negative predictive value were as follows: 41, 68, 31, and 77% for WBGC imaging; 45, 89, 59, and 82% for WBGC plus SPECT imaging; and 50, 100, 100, and 85% for WBGC plus SPECT/CT imaging respectively. The specificity was improved by the addition of SPECT (P=0.0002) and SPECT/CT (P<0.0001) than to WBGC imaging. SPECT/CT was also more specific than WBGC plus SPECT imaging (P=0.016). In a study-based analysis, SPECT/CT provided additional diagnostic information in 42% (36/85) of cases. SPECT/CT provided further characterization in 70% (63/90) of foci and improved the diagnostic confidence of all three observers. CONCLUSION The addition of SPECT/CT significantly improved the diagnostic information over Iodine-123 WBGC imaging and WBGC plus SPECT imaging alone.


International Journal of Urology | 2010

The clinical advances of fluorine‐2‐D‐deoxyglucose – positron emission tomography/computed tomography in urological cancers

Norbert Avril; Fatima Dambha; Iain Murray; Jonathan Shamash; Thomas Powles; Anju Sahdev

Fluorine‐18 labeled fluorine‐2‐D‐deoxyglucose (FDG) is the most frequently used positron emission tomography (PET) probe but it has certain limitations when used in urological cancers. The introduction of co‐registered PET and computed tomography (PET/CT) represents a major advance in technology and FDG‐PET/CT has now become the new standard. The diagnostic performance of FDG‐PET and PET/CT depends on the metabolic activity of tumor tissue, which is generally low in primary renal cell and prostate cancers and often in their metastatic deposits. In contrast, both seminomatous and nonseminomatous germ cell tumors are characterized by upregulated glucose metabolism with subsequently increased FDG uptake in tumor sites. Generally, the metabolic activity provides accurate information regarding the presence of a viable tumor, except in patients with residual mature teratoma. Although bladder cancer demonstrates sufficiently increased FDG uptake, primary tumors are difficult to identify due to the renal excretion of FDG. The accuracy of FDG‐PET/CT in metabolically active metastases is generally higher compared to conventional CT except for identifying small lung deposits. With disease progression and subsequent de‐differentiation of prostate cancer, castrate resistant disease is more likely to present with lesions that have increased glucose metabolism.


Cancer Biomarkers | 2011

FDG-PET/CT as a molecular biomarker in ovarian cancer.

Ewa Nowosinska; Stefanie Avril; Iain Murray; Teresa Szyszko; Norbert Avril

In the clinical setting the vast majority of positron emission tomography (PET) procedures use the glucose analogue F-18 fluorodeoxyglucose (FDG) to visualize the increased glucose consumption of malignant lesions. Co-registered PET/CT has improved the diagnostic accuracy compared to either imaging procedure alone, particularly in ovarian cancer. FDG-PET/CT demonstrates primary malignant ovarian tumors; however, it is often unable to accurately differentiate between benign and malignant pelvic masses and to visualize borderline ovarian tumors. FDG-PET/CT has a suggested role for staging, by improving treatment planning in individual cases, but it is particularly helpful in the setting of disease recurrence when CA125 tumor marker levels are rising and conventional imaging (CT or MR) is inconclusive or negative. The aim of this review is to demonstrate the value of FDG-PET-CT in diagnosis and management of patients with ovarian malignancies, outlining its advantages and limitations.


Nuclear Medicine Communications | 2013

Evaluation of a matched filter resolution recovery reconstruction algorithm for Spect-ct imaging

Eoin O’Mahoney; Iain Murray

AimThe aim of our study was to assess improvements in spatial resolution and noise control from the application of the Astonish resolution recovery algorithm for single photon emission computed tomography imaging. Secondary aims were to compare acquisitions made with low-energy general purpose collimators with those obtained using low-energy high-resolution collimators in this context and evaluate the potential of a finer matrix to improve image quality further. Materials and methodsA 99mTc-filled Jaszczak phantom with hot spheres was used to assess contrast and noise. A National Electrical Manufacturers Association triple line source single photon emission computed tomography resolution phantom was used to measure spatial resolution. Acquisitions were made using both low-energy high-resolution and low-energy general purpose collimators. ResultsCompared with standard ordered subsets expectation maximization reconstructions, the resolution recovery algorithm resulted in a higher spatial resolution (8 vs. 14 mm full-width at half-maximum) leading to reduced partial volume effects in the smaller Jaszczak spheres. Higher image contrast was achieved alongside lower levels of noise. An edge enhancement artefact was observed in the resolution recovery corrected images. An overestimate of the target-to-background activity was also observed for the larger spheres. ConclusionThe use of such an algorithm results in images characterized by increased spatial resolution and reduced noise. However, small sources of the order of 2–3 cm can be significantly overenhanced.


European Urology | 2007

Molecular Positron Emission Tomography and PET/CT Imaging in Urological Malignancies

Thomas Powles; Iain Murray; Cathryn Brock; Tim Oliver; Norbert Avril


European Journal of Nuclear Medicine and Molecular Imaging | 2010

Time-of-flight PET/CT using low-activity protocols: potential implications for cancer therapy monitoring

Iain Murray; Antonis Kalemis; Joe Glennon; Syed Hasan; Shuaib Quraishi; Thomas Beyer; Norbert Avril


Molecular Imaging and Biology | 2014

GRP Receptor Imaging of Prostate Cancer Using [ 99m Tc]Demobesin 4: a First-in-Man Study

Stephen J. Mather; Berthold A. Nock; Theodosia Maina; Vickie Gibson; David W. Ellison; Iain Murray; Ravin Sobnack; Steve Colebrook; Susan Wan; Gavin Halberrt; Teresa Szysko; Thomas Powles; Norbert Avril


Nuclear Medicine Communications | 2006

The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy.

Nidhal Ali; Cherry Sebastian; Rosemary R. Foley; Iain Murray; Canizales A; Paul J. Jenkins; William Drake; P. Nicholas Plowman; G. Michael Besser; Shern L. Chew; Ashley B. Grossman; J. P. Monson; K. E. Britton


European Journal of Nuclear Medicine and Molecular Imaging | 2017

The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Iain Murray; Sarah J. Chittenden; Ana M. Denis-Bacelar; Cecilia Hindorf; Chris Parker; Sue Chua; Glenn D. Flux


European Journal of Nuclear Medicine and Molecular Imaging | 2011

Reply to: The potential pitfalls of low-activity protocols in PET/CT imaging

Iain Murray; Norbert Avril

Collaboration


Dive into the Iain Murray's collaboration.

Top Co-Authors

Avatar

Norbert Avril

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Thomas Powles

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William Drake

St Bartholomew's Hospital

View shared research outputs
Top Co-Authors

Avatar

Ana M. Denis-Bacelar

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

Anju Sahdev

St Bartholomew's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Canizales A

St Bartholomew's Hospital

View shared research outputs
Top Co-Authors

Avatar

Cathryn Brock

Queen Mary University of London

View shared research outputs
Researchain Logo
Decentralizing Knowledge